Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 23, 2017 03:30 ET | Source: MediaPlatform, Inc.

MediaPlatform Adds Enterprise Webcasting Veteran Paul Reeves to Expand Sales Operations in EMEA

LOS ANGELES, CA--(Marketwired - May 23, 2017) - MediaPlatform (www.mediaplatform.com), the leading enterprise webcasting and video content management platform for internal communications in the Global...
May 23, 2017 01:00 ET | Source: INNATE PHARMA

Innate Pharma annonce la tenue de son Assemblée Générale Annuelle le 23 juin 2017 à Marseille

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} INNATE PHARMA ANNONCE LA TENUE DE...
May 23, 2017 01:00 ET | Source: INNATE PHARMA

Innate Pharma to hold its Annual General Meeting of shareholders on June 23, 2017

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} INNATE PHARMA TO HOLD ITS ANNUAL...
May 22, 2017 17:52 ET | Source: Sanofi Winthrop Industrie

Sanofi et Regeneron annoncent l'approbation par la FDA de Kevzara® (sarilumab) dans le traitement de la polyarthrite rhumatoïde active, modérée à sévère, de l'adulte

Sanofi et Regeneron annoncent l'approbation par la FDA de Kevzara® (sarilumab) dans le traitement de la polyarthrite rhumatoïde active, modérée à sévère, de l'adulte - Kevzara est désormais mis à...
May 22, 2017 17:52 ET | Source: Sanofi Winthrop Industrie

Sanofi and Regeneron Announce FDA Approval of Kevzara® (sarilumab) for the Treatment of Moderately to Severely Active Rheumatoid Arthritis in Adult Patients

Sanofi and Regeneron Announce FDA Approval of Kevzara® (sarilumab) for the Treatment of Moderately to Severely Active Rheumatoid Arthritis in Adult Patients - Kevzara is now available to U.S....
May 22, 2017 01:00 ET | Source: INNATE PHARMA

INNATE PHARMA : IPH4102 : Fin de la partie en escalade de dose de l'essai de phase I - Présentation au Congrès International de Lugano

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} IPH4102 : FIN DE LA PARTIE en ESCALADE...
May 22, 2017 01:00 ET | Source: INNATE PHARMA

INNATE PHARMA : IPH4102: Completion of the dose escalation part of the phase I trial - Data to be presented at ICML in June 2017 in Lugano

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} IPH4102: Completion of THE dose...
May 19, 2017 07:09 ET | Source: Sanofi Winthrop Industrie

Sanofi Receives CHMP Recommendation for Approval of Insulin Lispro Biosimilar

Sanofi Receives CHMP Recommendation for Approval of Insulin Lispro Biosimilar - Positive opinion based on a clinical development program involving over 1,000 people with type 1 or type 2 diabetes -...
May 19, 2017 07:09 ET | Source: Sanofi Winthrop Industrie

Sanofi: le CHMP recommande l'approbation de l'insuline lispro biosimilaire de Sanofi

Le CHMP recommande l'approbation de l'insuline lispro biosimilaire de Sanofi - Un avis favorable fondé sur les résultats du programme de développement clinique auquel ont pris part plus de 1 000...
May 19, 2017 05:40 ET | Source: Research and Markets

Global Needle-Free Drug Injection Systems Strategic Business Report 2017-2022

Dublin, May 19, 2017 (GLOBE NEWSWIRE) -- Research and Markets has announced the addition of the "Needle-Free Drug Injection Systems - Global Strategic Business Report" report to...